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von Willebrand factor (vWF) is a large glycoprotein secreted predominantly by endothelial cells in both the systemic 
and pulmonary circulations and has a central role in the formation of the platelet plug. It has been put forward as 
a possible marker of endothelial cell injury, but is not ideal in that it is not specific for either the pulmonary or 
systemic circulation and may be released as part of the acute phase response from otherwise healthy endothelial cells. 
We undertook two studies (i) to assess within-subject variation in plasma von Willebrand factor antigen 
(vWF:Ag) levels over time and to assess between-subject variation in a healthy patient population, and (ii) as part 
of a descriptive study of acute bronchitis, to assess whether plasma vWF:Ag levels altered in such a common and 
minor insult. 
A random sample of patients aged 45-74 years were taken from a local general practice. vWF:Ag levels were 
measured on three occasions, and spirometry was performed. The descriptive study was undertaken on patients in 
the general practice diagnosed with acute bronchitis without pre-existing pulmonary disease. Plasma vWF:Ag was 
measured on presentation and 14 and 42 days later. 
In 219 randomly selected patients the mean plasma vWF:Ag was similar at all three visits, the within-subject 
standard deviation being 0.09 U ml - ‘. vWF:Ag levels rose significantly with age (r2=0.29, P<O.Ol). In 39 patients 
with acute bronchitis, the plasma vWF:Ag level at presentation (1.51 U ml - ‘) was significantly higher than at 2 and 
6 weeks later (1.06 U ml - ’ and 1.12 U ml - ’ respectively). There was no correlation between plasma vWF:Ag and 
C-reactive protein on presentation. 
We conclude that there is relatively little variation in an individual’s plasma vWF:Ag level but that levels increase 
significantly with age. The observed elevation occurring with acute bronchitis is a true phenomenon; the absence of 
an associated acute phase response suggests that endothelial cell injury is the mechanism for the rise. These 
observations are important in the context of vWF as a marker of endothelial cell damage, as a common and 
supposedly minor insult such as acute bronchitis may markedly raise plasma levels. 
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Introduction 
von Willebrand factor (vWF) is a large glycoprotein which 
is produced predominantly by endothelial cells in both the 
pulmonary and systemic vasculature, and in platelets (1). It 
is made up of subunits, varying in molecular weight from 
0.5 to 20 x lo3 kDa. Loss of the larger subunits results in 
loss of biological activity (e.g. in type II von Willebrand’s 
disease) (2,3). Quantitative levels of vWF may be assayed as 
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vWF antigen (vWF:Ag), while biological activity may be 
assessed with ristocetin cofactor activity. 
In endothelial cells, vWF is stored in Wiebel-Palade 
bodies and is released predominantly in situations where 
haemostasis is threatened, when it binds to the platelet 
membrane glycoprotein GPlb, thus activating the platelet 
and leading to irreversible platelet binding. The resulting 
platelet plug is the primary unit of haemostasis (3). 
vWF may also be released by direct injury to endothelial 
cells (systemic or pulmonary) or when endothelial dysfunc- 
tion is present. Thus, increased levels of vWF:Ag have been 
found in numerous clinical settings where endothelial dys- 
function or mechanical damage are presumed, including 
hypertension (both pulmonary (46) and systemic (7,8)), 
abnormal cardiovascular haemodynamics associated with 
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valvular disease (9), hypercholesterolaemia (10) and high 
altitude pulmonary oedema (11). 
vWF is also released by the action of mediators such as 
interleukin-1 during the acute phase response (12-14). 
There are therefore a number of clinical situations where 
increased vWF:Ag levels could result from either cytokine- 
mediated release or from direct endothelial damage (15). In 
diseases such as sepsis-related ARDS (16,17), acute respir- 
atory failure with other aetiologies (18) in the vasculitides 
(especially systemic sclerosis (19,20)) and following cardio- 
pulmonary bypass (21), vWF:Ag levels have been shown to 
be raised. The mechanism in these cases is likely to be 
endothelial damage, but release by acute-phase mediators is 
difficult to exclude. 
It has been suggested that vWF is a useful marker of 
endothelial damage (13). However, the major problems 
with its use in this respect are its release during the acute 
phase and its release from both systemic and pulmonary 
endothelium (15). vWF:Ag levels have been used to predict 
the development of ARDS in non-pulmonary sepsis with 
varying success, and increased specificity for pulmonary 
endothelial damage rather than systemic damage has been 
suggested by these studies (16,17,22,23). They have also 
been used to follow the progress of disease in patients with 
systemic sclerosis, and have recently been correlated with 
risk of re-infarction and mortality in patients surviving 
acute myocardial infarction (24). 
In platelets, vWF is stored in a granules. It has been 
postulated that release of vWF from platelets during aggre- 
gation and degranulation may contribute to raised levels of 
vWF:Ag in the above clinical conditions, but the contribu- 
tion to plasma levels by this mechanism is likely to be small 
(13,25). Jones et al. found that intravenous prostacyclin (a 
potent inhibitor of platelet aggregation) failed to suppress 
the release of vWF following cardio-pulmonary bypass 
(21). 
As part of a large community-based study (26) we sought 
to assess (i) within-subject and between subject variation 
in vWF:Ag levels in healthy subjects, and (ii) the effect 
of a common and relatively minor insult such as acute 
bronchitis on vWF:Ag levels. 
Methods 
PATIENTS 
Study I - Sample Population 
A respiratory symptom questionnaire was sent to all 2242 
patients aged 45-74 years, identified by the age/sex register 
in an inner city general practice with a practice population 
of 7700. A question was included on whether the patient 
would be willing to attend the surgery for simple breathing 
and blood tests. From the positive responders, a l-in-6 
sample was selected, using random number tables, to attend 
for further investigation. No restrictions were placed on 
individuals with respect to smoking status or activity level. 
Of the 251 patients selected to attend, 219 (87.1%) 
attended. The mean (SD) age was 60 years ( f 8.8) and 117 
(53%) were female. 
Study 2 - Acute Bronchitis 
A descriptive study of acute bronchitis was undertaken 
between September 1986 and March 1987 in the same 
general practice. A total of 39 patients were recruited, all of 
whom satisfied the American Thoracic Society’s definition 
of acute bronchitis (27). Episodes of acute bronchitis in 
patients with previously diagnosed pulmonary disease, such 
as asthma or chronic obstructive airways disease, were 
excluded from the study. Details of this study have been 
published previously (26). 
The mean age of the 39 patients was 38.4 years (range 
5-73 years) and 27 (69%) of the episodes occurred in 
women. 
Both studies were approved by the local Ethics 
Committee. 
INVESTIGATIONS 
Study 1 - Sample Population 
Venous blood was taken at three morning visits to the 
clinic, each separated from the other by at least 7 days, for 
plasma vWF:Ag estimation. In addition, simple pulmonary 
function tests (FEV,, FVC) were performed using a 
Vitalograph dry bellows spirometer, with at least two 
attempts reproducible to within 200 ml or 5% (whichever 
was smaller). Peak expiratory flow (PEF) was recorded on a 
Wright mini-peak flow meter, with at least two attempts 
reproducible to within 20 1 min - ‘. Exhaled breath carbon 
monoxide levels were measured (Morgan Ecocheck) to 
confirm the smoking history. 
Study 2 - Acute Bronchitis 
Written informed consent was obtained from all patients. 
Spirometry was performed at all three visits. Pathogens 
were sought using nasopharyngeal washings, sputum cul- 
ture where possible, and viral serology. Venous blood was 
taken for plasma vWF:Ag and CRP on presentation and 6 
weeks later, and for plasma vWF:Ag alone at an interim 
visit 2 weeks after presentation. 
LABORATORY METHODS 
Five millilitres of titrated blood (one part 3.9% sodium 
citrate to nine parts blood) was taken for vWF:Ag measure- 
ment. After centrifugation at 1500 g for 15 min, platelet- 
poor plasma was separated and stored at - 20°C being 
thawed at 37°C immediately prior to assay. Plasma 
vWF:Ag was measured using an ELISA method (28) 
which has a coefficient of variation between batches and 
within batches of less than 5%. A single batch of standard 
was used throughout, having been re-constituted to a 
vWF:Ag level of 1.00 U ml ~ ‘, and a control preparation of 
plasma with a vWF:Ag level of I.00 U ml - i (Immuno- 
diagnostics) was assayed with each batch of test samples. 
vWF:Ag multimers were examined as described previously 
(29). CRP was estimated turbidimetrically using a 
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mono-specific antiserum to CRP raised in sheep (BDS, 
Birmingham). 
ANALYSIS 
Study 1 - Healthy Population 
vWF:Ag results are expressed as the mean and the standard 
deviation. Ninety-five and 99% CI were calculated for the 
effect of age on plasma vWF:Ag. The Shapiro-Wilk test 
was performed on the vWF:Ag data for each visit, which 
demonstrated no significant differences, so the data could 
be assumed to follow a normal distribution. An analysis of 
variance (ANOVA) was carried out to analyse vWF:Ag 
variation over the three measurements, and the residual 
mean square from this procedure taken to calculate the 
within-subject standard deviation (measurement error) and 
the repeatability (the difference between paired observa- 
tions is expected to be less than this figure 95% of the time) 
as suggested by Bland and Altman (30). Student’s unpaired 
t-test was used to assess the effect of smoking, gender and 
the presence of respiratory symptoms on plasma vWF:Ag. 
Pulmonary function results were analysed as actual values, 
the percentage predicted, and standardized residuals (31), 
and linear regression analysis was undertaken to assess 
whether there was a relationship between any of these 
variables or age and plasma vWF:Ag levels. 
Study .Z - Acute Bronchitis 
Plasma vWF:Ag results are expressed as the mean and the 
standard error of the mean. For the differences between two 
means, the 95% confidence intervals (CI) have also been 
calculated. A split-plot analysis of variance (ANOVA) was 
used for repeated measure of vWF:Ag, and Tukey’s pro- 
cedure was performed to determine the significance of 
time and smoking status on the mean plasma vWF:Ag. 
McNemars test was used to determine whether there was a 
relationship between a raised plasma vWF:Ag level and a 
raised plasma CRP result. 
Results 
Study 1 - Sample Population 
In the study population of 219, the mean percent predicted 
FEV, was 92.2% and FVC 100.2%. 
The mean (SD) plasma vWF:Ag levels were 1.09 (0.22), 
1.10 (0.20) and 1.10 (0.19) U ml-’ for the three visits 
(n=212, 203 and 195 respectively). The results were nor- 
mally distributed (Shapiro-Wilk test), and ANOVA dem- 
onstrated no difference between the vWF:Ag blood levels at 
any of the three visits. Only 14/610 (0.7%) measurements 
of plasma vWF:Ag were outside the normal range for 
our laboratory (0.5-1.5 U ml ~ ‘). The within-subject stan- 
dard deviation (measurement error) was moderate at 
0.09 U ml - ’ and the repeatability was 0.25 U ml - ‘. 
Plasma vWF:Ag levels increased with age (v2=0.29, 
PcO.01: Fig. 3), but did not relate to smoking status, 
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FIG. 1. vWF:Ag levels on presentation in patients with 
acute bronchitis and at follow-up 2 and 6 weeks later 
[means (SE)]. 
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FIG. 2. CRP and plasma vWF:Ag levels on presentation 
in patients with acute bronchitis (data available on 32 of 
the 39 patients). 
exhaled carbon monoxide level, or any measure of pulmon- 
ary function. Patients who responded positively to the 
question ‘Are you troubled by shortness of breath when 
hurrying on level ground or walking up a slight hill?’ had 
significantly higher plasma vWF:Ag levels at each of three 
visits than did those patients with a negative reply (1.12 
vs. 1.06, 1.13 vs. 1.07 and 1.14 vs. 1.07: PcO.02) for each 
visit, but regression analysis revealed that this association 
was due to age. There was no relationship between plasma 
vWF:Ag levels and any other questionnaire responses. 
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FIG. 3. Confidence intervals (CI) for the effect of age on 
plasma vWF:Ag level. r2=0.29, BO.01. 
Study 2 - Acute Bronchitis 
The mean percent predicted FEY, and FVC rose 
significantly between presentation and follow-up 2 
weeks later (FEV, 86.9% predicted to 91.6% predicted 
(PcO.01) and FVC 90.8% predicted to 94.7% predicted 
(PCO.02)). 
Three of the 39 patients did not receive microbiological 
assessment; however, a potential pathogen was identified in 
13 of the 36 (36%) fully investigated patients: eight viral 
infections (rhinovirus, influenza A and adenovirus), four 
Mycoplasma pneumoniae and three bacterial infections 
(Haemophilus injluenzae, Branhamella catarrhalis and 
Streptococcus pneumoniae), two in association with a 
virus (26). 
The mean (SEM) plasma vWF:Ag on presentation was 
1.51 (0.15) Uml-‘, falling to 1.06 (0.11) Umll’ at 2 
weeks (mean difference 0.45 U ml - ‘, 95% CI from 0.24 to 
0.66). At 6 weeks, the value was 1.12 (0.11) U ml- ’ (mean 
difference 0.36 U ml - ’ from presentation, 95% CI 0.18 to 
0.54). Split-plot ANOVA confirmed highly significant dif- 
ferences between the results at presentation, at 2 weeks and 
6 weeks. Tukey’s procedure demonstrated that the mean at 
presentation was significantly different from those at 2 
weeks and at 6 weeks (P<O.O5), but there were no differ- 
ences between the means at 2 and at 6 weeks. Plasma 
vWF:Ag levels exceeded the normal range in 11 (28%) at 
presentation. In contrast to the larger control population, 
split-plot ANOVA demonstrated a significant effect of 
smoking, with Tukey’s procedure confirming that the 
means in ex-smokers were significantly greater than the 
means in current smokers and life-long non-smokers 
(P~0.05). The plasma vWF:Ag levels at 6 weeks were 
higher in older patients regardless of their smoking status 
(rz0.543; P<O.OOl). 
Multimeric analysis in three cases, two of whom had 
elevated levels on presentation, demonstrated a normal 
pattern of vWF:Ag multimers. 
There was no relationship between a raised plasma 
vWF:Ag level and a raised serum CRP on presentation 
(Fig. 1). CRP was minimally elevated in five patients on 
presentation, and markedly raised in one case (84 mg 1 - ‘); 
however, all of these patients had normal vWF:Ag levels. 
Equally, of the 11 patients who had elevated vWF:Ag 
levels, all had normal CRP. 
There was moderate within-subject variation in vWF:Ag 
levels (0.09 U ml - ‘, repeatability 0.25 U ml - ’ in healthy 
subjects, but less variation than has been observed pre- 
viously with either exercise (32,33), or acute smoking (34). 
Work examining the effect of exercise has involved strenu- 
ous exercise, such as running up and down stairs for 3 min 
(33), or running half a mile as fast as possible (32) in young 
subjects. These studies have demonstrated quite consider- 
able increases in plasma vWF:Ag levels ranging from 46 to 
300%. It is believed that these changes are mediated via 
&receptors (35) and that the rise is due to release from 
endothelial cells rather than activation in the plasma (36). 
In a previous study examining distributions of haemostatic 
variables in a population for the development of reference 
ranges (37), smokers were found to have lower plasma 
vWF:Ag levels than non-smokers. However, for regular 
smokers, smoking three cigarettes within 30 min produced a 
significant increase in plasma vWF:Ag (34). In our study, 
although ex-smokers with acute bronchitis had higher 
plasma vWF:Ag levels (P<O.O5), the much larger sample 
population of healthy individuals revealed plasma vWF:Ag 
levels which were similar in smokers, ex-smokers and 
life-long non-smokers. For current smokers, there was no 
correlation between plasma vWF:Ag and exhaled breath 
carbon monoxide, suggesting that, while cigarettes may 
have an effect in strictly controlled experimental situations, 
this may be of less relevance in a clinical setting. 
Our study confirms work demonstrating that vWF:Ag 
levels rise with increasing age (37,38). As noted in these 
previous studies, this may be due to a cohort effect rather 
than chronological age, and longitudinal studies are 
required to examine this point. The ‘normal’ range, encom- 
passing 95% of the values in our study is 0.641.54 U ml ~ ‘, 
slightly higher than the reference range for our laboratory, 
and is probably due to the older age of our patients. 
Patients with acute bronchitis showed a statistically sig- 
nificant 40% increase in vWF:Ag levels with their acute 
illness. The most obvious explanation is that this is simply 
part of the acute phase response: a non-specific cytokine- 
mediated response to microbial infection which includes an 
increase in the synthesis and secretion of a number of 
plasma proteins, predominantly by hepatocytes (3941). 
CRP is the classic acute phase protein, secreted 
within 6 h of an acute insult and often in sufficient quan- 
tities to raise the plasma level over 100 fold (39,40). 
However, we found no correlation between CRP levels 
and vWF:Ag levels in patients with acute bronchitis, 
suggesting that vWF release was not caused by acute phase 
mediators. 
Changes in CRP are useful in differentiating between 
bacterial and viral infections, particularly in children, since 
viral infections rarely produce a change in serum CRP 
levels (39,42-44). Since the majority of cases of acute 
bronchitis are presumed to be viral in origin, it is not 
surprising that CRP levels remained normal in most cases 
investigated in this study. A study involving inoculation of 
rhinovirus to assess the effect of interferon-y in preventing 
the development of the common cold demonstrated 
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no correlation between peak CRP levels and vWF:Ag 
levels (12). 
When vWF levels rise in the acute phase, the pattern of 
increase is slightly different from CRP during acute infec- 
tion (12) is different from the acute phase protein 
a-1-antichymotrypsin following cardio-pulmonary bypass 
(21) and different from other coagulation proteins following 
acute tissue necrosis, such as acute myocardial infarction 
(45,46). It is possible, therefore, that given the different time 
course for secretion of vWF and CRP, a single measure- 
ment may miss either peak. More frequent measurements 
would be needed to discount this possibility. 
The two other possible sources of vWF are platelets and 
damaged endothelium. As already described, platelets 
probably contribute only a very small amount of vWF to 
the plasma pool, especially in a minor insult such as acute 
bronchitis where widespread platelet degranulation is 
extremely unlikely. We therefore postulate that the infective 
agents in acute bronchitis have a direct effect on endothelial 
cells to cause release of vWF. The bronchial tree from 
bronchi down to respiratory bronchioles receives its arterial 
supply from the systemic circulation via the bronchial 
arteries. Endothelial cells damaged during acute bronchitis 
would therefore be of systemic origin. 
In summary, plasma vWF:Ag shows relatively little 
within-subject variation in the general population, and, in 
particular, does not appear to be influenced by normal daily 
activity, or by smoking status. Levels increase with age, 
although longitudinal data are required to confirm this 
observation. A minor insult such as acute bronchitis raises 
plasma vWF:Ag levels by 40%. Our data suggest that this is 
not simply a part of the acute phase response, but a result of 
systemic endothelial damage in the bronchial circulation. 
These observations are important in the context of vWF as 
a putative marker of endothelial cell damage. 
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